Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

NCT06639555 is registered in ClinicalTrials.gov with Tsvetalina Gerova-Vatsova as lead sponsor.

NCT NCT06639555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects
Lead sponsor
Tsvetalina Gerova-Vatsova
Phase
Not applicable
Overall status
Completed
Start date
June 24, 2022
Completion date
August 15, 2023
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vertical alveolar bone loss